Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6)

Patrick A. Brown, John A. Kairalla, Joanne M. Hilden, Zo Ann E. Dreyer, Andrew J. Carroll, Nyla A. Heerema, Cindy Wang, Meenakshi Devidas, Lia Gore, Wanda L. Salzer, Naomi J. Winick, William L. Carroll, Elizabeth A. Raetz, Michael J. Borowitz, Donald Small, Mignon L. Loh, Stephen P. Hunger

Research output: Contribution to journalComment/debatepeer-review

Fingerprint Dive into the research topics of 'Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6)'. Together they form a unique fingerprint.

Medicine & Life Sciences